Innate Pharma (IPHA) Change in Intangibles (2019 - 2023)

Innate Pharma (IPHA) has 5 years of Change in Intangibles data on file, last reported at -$2.2 million in Q4 2023.

• Quarterly Change in Intangibles fell 259.31% year-over-year to -$2.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$3.2 million (up 75.87% YoY) and the FY2023 annual result came in at -$2.2 million, changed N/A from the prior year.
• Change in Intangibles eased to -$2.2 million in Q4 2023, from -$598885.2 in the prior quarter.
• In the past five years, Change in Intangibles ranged from a high of -$39741.0 in Q2 2021 to a low of -$72.1 million in Q2 2019.
• A 5-year average of -$21.1 million and a median of -$6.2 million in 2020 frame the typical range for Change in Intangibles.
• Annual changes were most pronounced in 2021 — Change in Intangibles surged 99.61% — and 2023, when it slumped 259.31%.
• Tracing IPHA's Change in Intangibles over 5 years: stood at -$71.0 million in 2019, then jumped by 82.57% to -$12.4 million in 2020, then jumped by 96.29% to -$458732.4 in 2021, then tumbled by 30.55% to -$598885.2 in 2022, then tumbled by 259.31% to -$2.2 million in 2023.
• The last three Change in Intangibles figures came in at -$2.2 million (Q4 2023), -$598885.2 (Q4 2022), and -$458732.4 (Q4 2021), per Business Quant data.